Apply now
Identification or Validation of Targets for Personalised Medicine Approaches
The call (JTC2024) will aim to fund research that fosters the identification or validation of targets for personalised medicine approaches. Applicants submitting a proposal to this call must combine the research on new and advanced targets with companion biomarker research (companion diagnostics). Consortia are required to be transnational, interdisciplinary and trans-sectoral as well as to clearly outline the personalised medicine perspective in the research proposed.
The overall objectives of the JTC2024 are to
- Support research projects aiming at identifying or validating targets for personalised medicine approaches in combination with development of companion biomarkers or other markers to allow for monitoring of treatment outcomes and patient stratification;
- Encourage and enable interdisciplinary collaborations by combining pre-clinical and clinical research in translational projects, and multi-actor research by engaging a range of other relevant disciplines such as bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to empower the implementation of PM; and
- Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations.
Research projects in all disease areas are encouraged.
All applicants and partners must comply with the State Aid rules. All projects are to be carried out as effective collaboration between the partners. Undertakings (companies) that participate in the consortium must also not receive indirect state aid in the form of advantageous conditions for cooperation with the research institutions taking part in the consortium. Conditions for awarding state aid (forskningsradet.no)
See the full announcement: https://www.eppermed.eu/jtc2024/